Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Chengdu Kanghong Biotechnology, has received approval from the National Medical Products Administration for the clinical trial of KH816 injection, a biosimilar to Dupilumab [1] Group 1: Product Development - KH816 injection is developed as a biosimilar to Dupilumab, which is a fully human monoclonal antibody (IgG4 type) [1] - The mechanism of action involves specific binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes, inhibiting the signaling pathways of IL-4 and IL-13 [1] Group 2: Therapeutic Applications - IL-4 and IL-13 mediated inflammation is a significant component in the pathogenesis of asthma, atopic dermatitis, nodular prurigo, and chronic obstructive pulmonary disease [1] - The inflammatory response involves various cell types expressing IL-4Rα, including mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, and goblet cells, as well as inflammatory mediators such as histamine, leukotrienes, cytokines, and chemokines [1] Group 3: Mechanism of Action - By blocking IL-4Rα, Dupilumab can inhibit the inflammatory responses induced by IL-4 and IL-13 cytokines, including the release of pro-inflammatory cytokines, chemokines, nitric oxide, and IgE [1]

Core Viewpoint - Kanghong Pharmaceutical announced that its wholly-owned subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., received approval from the National Medical Products Administration for clinical trials of KH816 injection, a biosimilar of Dupilumab, targeting moderate to severe atopic dermatitis in adults [1]. Group 1 - The approval allows for the clinical trial of KH816 injection [1] - KH816 is developed as a biosimilar to Dupilumab [1] - The targeted clinical indication is for adult patients with moderate to severe atopic dermatitis [1]

Group 1 - The core point of the article is that Kanghong Pharmaceutical's subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., has received a clinical trial approval notice from the National Medical Products Administration for the drug KH816 injection [1] Group 2 - Kanghong Pharmaceutical announced the approval on January 14, indicating progress in their drug development pipeline [1] - The article also highlights a separate case involving Haili Biotechnology, which has seen a significant valuation drop despite a previous ninefold increase due to unusual circumstances surrounding its largest client [1]

Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Chengdu Kanghong Biotechnology Co., has received approval from the National Medical Products Administration for clinical trials of KH816 injection, a biosimilar to Dupilumab [1] Group 1: Product Development - KH816 is developed as a biosimilar to Dupilumab, which is a fully human monoclonal antibody (IgG4 type) [1] - The mechanism of action involves specific binding to the IL-4Rα subunit shared by IL-4 and IL-13 receptor complexes, inhibiting the signaling pathways of IL-4 and IL-13 [1] Group 2: Therapeutic Applications - IL-4 and IL-13 mediated inflammation is a significant component in the pathogenesis of asthma, atopic dermatitis, nodular prurigo, and chronic obstructive pulmonary disease [1] - The inflammatory response involves various cell types expressing IL-4Rα, including mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, and goblet cells, as well as inflammatory mediators such as histamine, leukotrienes, cytokines, and chemokines [1] Group 3: Mechanism of Action - By blocking IL-4Rα, Dupilumab can inhibit the inflammatory responses induced by IL-4 and IL-13 cytokines, including the release of pro-inflammatory cytokines, chemokines, nitric oxide, and IgE [1]

证券代码：002773 证券简称：康弘药业 公告编号：2026-003 受理号：CXSL2500953 成都康弘药业集团股份有限公司 关于子公司收到药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 近日，成都康弘药业集团股份有限公司（以下简称"公司"）全 资子公司成都康弘生物科技有限公司（以下简称"康弘生物"）收到 国家药品监督管理局签发的《药物临床试验批准通知书》。现将相关 情况公告如下： 一． 药品基本信息 药品名称：KH816 注射液 剂型：注射剂 批准开展临床适应症：成人中重度特应性皮炎 注册分类：治疗用生物制品 3.3 类 成都康弘药业集团股份有限公司董事会 2026 年 1 月 14 日 审批结论：同意开展临床试验。 二． 产品简介 KH816 注射液是康弘生物研发的度普利尤单抗生物类似药。度普 利尤单抗是一种全人单克隆抗体（IgG4 型），可通过与白介素-4（IL-4） 和白介素-13（IL-13）受体复合物共享的 IL-4Rα 亚单位特异性结 合而抑制 IL-4 和 IL-13 的信号传导。度普利尤单抗通过 I 型受 ...

Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd.'s subsidiary, Chengdu Hongji Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for its KH631 eye injection for the treatment of Diabetic Macular Edema (DME) [1] Group 1 - The approved indication for KH631 is specifically for Diabetic Macular Edema (DME) [1]

证券日报网讯 1月12日，康弘药业在互动平台回答投资者提问时表示，截至2026年1月9日，公司股东户 数为33118户。 （文章来源：证券日报） ...

成都康弘药业集团股份有限公司 Chengdu Kanghong Pharmaceutical Group Co., Ltd 成都市金牛区蜀西路 108 号 章 程 2025 年 12 月 | ਮ | | --- | | | 成都康弘药业集团股份有限公司章程 | 3 | | --- | --- | --- | | 第一章 | 总 则 | 3 | | 第二章 | 经营宗旨和范围 | 4 | | 第三章 | 股 份 | 4 | | 第四章 | 股东和股东会 | 9 | | 第五章 | 董事会 | 26 | | 第六章 | 高级管理人员 | 39 | | 第七章 | 党的建设 | 41 | | 第八章 | 财务会计制度、利润分配和审计 | 42 | | 第九章 | 通知和公告 | 45 | | 第十章 | 合并、分立、增资、减资、解散和清算 46 | | | 第十一章 | 修改章程 | 50 | | 第十二章 | 附 则 51 | | 成都康弘药业集团股份有限公司章程 成都康弘药业集团股份有限公司章程 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织 和行为，根据《中华人民共和国公司法 ...

Core Viewpoint - Kanghong Pharmaceutical has shown a positive stock performance with a year-to-date increase of 13.65% and a market capitalization of 31.38 billion yuan as of January 9 [1]. Financial Performance - For the period from January to September 2025, Kanghong Pharmaceutical achieved a revenue of 3.624 billion yuan, representing a year-on-year growth of 6.23%. The net profit attributable to shareholders was 1.033 billion yuan, with a year-on-year increase of 6.08% [2]. Shareholder Information - As of December 31, the number of shareholders for Kanghong Pharmaceutical reached 28,900, an increase of 1.32% from the previous period. The average number of circulating shares per shareholder decreased by 1.30% to 23,805 shares [2]. Dividend Distribution - Since its A-share listing, Kanghong Pharmaceutical has distributed a total of 2.038 billion yuan in dividends, with 1.04 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 28.007 million shares, an increase of 730,000 shares from the previous period. Other notable shareholders include Dachen Rui Xiang Mixed A and Dachen Competitive Advantage Mixed A, which saw reductions in their holdings [3].

证券日报网讯 1月8日，康弘药业发布公告称，公司于2025年12月3日召开第八届董事会第十四次会议、 2025年12月19日召开二〇二五年第一次临时股东会审议通过了《关于变更公司注册资本及修订〈公司章 程〉的议案》。公司于近日完成了公司章程的相关工商变更登记手续。 （文章来源：证券日报） ...